With a bit of time in hand, I re-read the latest Company...

With a bit of time in hand, I re-read the latest Company Presentation again. And I note one very critical near term milestone. If achieved successfully, then PCK will definitely be revenue positive end 2020/early 2021, even allowing for more growth in cost of operation. That milestone is Launch Direct To Carer (DTC) version of PainChek to the Aussie and European markets in 2H 2020. According to the presentation, there are 5.9m dementia patients living at home in the Aussie and European markets. Unlike aged care business, these home carers/users will not bat an eyelid to spend $120 per year for their loved ones. According to presentation:

PCK get net $7 monthly subscription after app store take their cuts.
That is $7 x 12 = $84/year subscription.
1% of that market = $84 x 59,000 = almost $5m revenue.
2% will be almost $10m and so on.
AND...in 2021, the US market will come to play as well.

The mind boggles over what is in store for PCK over the next couple of years. It is with these sort of potential fundamentals that make PCK such a compelling investment.